Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1345951 | 0.88 | MAPT (0.54) | MAPTMCL1JAK2JAK1KMT2A | |
| SCHEMBL1345355 | 0.87 | MAPT (0.54) | MAPTMCL1JAK2JAK1KMT2A | |
| SCHEMBL4784285 | 0.81 | TP53 (0.55) | MAPTMCL1KMT2ATP53MEN1 | |
| SCHEMBL1345627 | 0.80 | MAPT (0.57) | MAPTMCL1KMT2ATP53MEN1 | |
| SCHEMBL1345870 | 0.80 | RAB9A (0.60) | MAPTKMT2ATP53MEN1RAB9A | |
| SCHEMBL1346632 | 0.79 | KMT2A (0.56) | MAPTKMT2ATP53MEN1RAB9A | |
| SCHEMBL2993892 | 0.79 | HTR6 (0.49) | MAPTHTR6RAB9AMAPKAPK2NPC1 | |
| SCHEMBL1345681 | 0.78 | MAPT (0.59) | MAPTMCL1KMT2ATP53MEN1 | |
| SCHEMBL1345311 | 0.78 | PRNP (0.47) | MAPTJAK2JAK1KMT2ATP53 | |
| SCHEMBL1345168 | 0.78 | POLB (0.56) | MAPTJAK2JAK1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063094-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2008098096-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | MAPKAPK2, IL2, MAP3K2 | MAPT 2259/4885MCL1 658/4885JAK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.